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Abstract
Objective To evaluate differences in first manifestations of cardiovascular
disease between men and women in a competing risks framework.
Design Prospective population based cohort study.
Setting People living in the community in Rotterdam, the Netherlands.
Participants 8419 participants (60.9% women) aged ≥55 and free from
cardiovascular disease at baseline.
Main outcome measures First diagnosis of coronary heart disease
(myocardial infarction, revascularisation, and coronary death),
cerebrovascular disease (stroke, transient ischaemic attack, and carotid
revascularisation), heart failure, or other cardiovascular death; or death
from non-cardiovascular causes. Data were used to calculate lifetime
risks of cardiovascular disease and its first incident manifestations
adjusted for competing non-cardiovascular death.
Results During follow-up of up to 20.1 years, 2888 participants
developed cardiovascular disease (826 coronary heart disease, 1198
cerebrovascular disease, 762 heart failure, and 102 other cardiovascular
death). At age 55, overall lifetime risks of cardiovascular disease were
67.1% (95% confidence interval 64.7% to 69.5%) for men and 66.4%
(64.2% to 68.7%) for women. Lifetime risks of first incident manifestations
of cardiovascular disease in men were 27.2% (24.1% to 30.3%) for
coronary heart disease, 22.8% (20.4% to 25.1%) for cerebrovascular
disease, 14.9% (13.3% to 16.6%) for heart failure, and 2.3% (1.6% to
2.9%) for other deaths from cardiovascular disease. For women the
figures were 16.9% (13.5% to 20.4%), 29.8% (27.7% to 31.9%), 17.5%
(15.9% to 19.2%), and 2.1% (1.6% to 2.7%), respectively. Differences
in the number of events that developed over the lifespan in women
compared with men (per 1000) were −7 for any cardiovascular disease,
−102 for coronary heart disease, 70 for cerebrovascular disease, 26 for
heart failure, and −1 for other cardiovascular death; all outcomes
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manifested at a higher age in women. Patterns were similar when
analyses were restricted to hard atherosclerotic cardiovascular disease
outcomes, but absolute risk differences between men and women were
attenuated for both coronary heart disease and stroke.
Conclusions At age 55, though men and women have similar lifetime
risks of cardiovascular disease, there are considerable differences in
the first manifestation. Men are more likely to develop coronary heart
disease as a first event, while women are more likely to have
cerebrovascular disease or heart failure as their first event, although
these manifestations appear most often at older ages.
Introduction
For both men and women, cardiovascular disease remains one
of the leading causes of death and disability in Western
societies.1 2 Considerable sex differences exist, however, in the
occurrence of the various manifestations of cardiovascular
disease. Men have a higher risk of coronary heart disease than
women, especially at younger ages.3Women, on the other hand,
have a similar or greater propensity for developing stroke4 and
heart failure.5 6 Because strategies for prevention of stroke and
heart failure might differ from strategies for prevention of
coronary heart disease, knowledge about the first manifestation
of cardiovascular disease is important for primary prevention
purposes. Population based data on sex differences in
cardiovascular disease are scarce for the various first
manifestations of cardiovascular disease.
Women have a higher life expectancy than men and
consequently have more time to develop cardiovascular disease.
Cardiovascular risk factors, such as smoking, not only increase
the susceptibility for cardiovascular disease but are also
associated with an increased risk of dying from
non-cardiovascular causes before the development of
cardiovascular disease.7 8 Therefore, in comparisons of first
manifestations of cardiovascular disease, competing risks among
the different manifestations and death from non-cardiovascular
causes cannot be neglected. To date no studies have compared
multiple first manifestations of cardiovascular disease between
men and women in a competing risks framework.
We used long term follow-up data from the prospective
population based Rotterdam Study to calculate the lifetime risks
of cardiovascular disease and the first incident manifestations
of cardiovascular disease in middle aged and elderly men and
women.
Methods
Study design, setting, and population
This study was performed within the Rotterdam Study, a
prospective population based cohort designed to study the
occurrence and determinants of age related diseases in the
general population. Details regarding the objectives and design
have been reported previously.9 10 Briefly, for the initial cohort
(RS-I) all inhabitants aged ≥55 from a well defined suburb in
the city of Rotterdam, Netherlands, received an invitation to
participate, and 7983 (78.1%) were enrolled. Levels of
participation at baseline did not differ for men and women but
were lower with increasing age.11 From 1990 to 1993, baseline
data were collected during standardised home interviews and
two visits to the research centre. Starting in 2000, the Rotterdam
Study was extended with a second cohort (RS-II) of inhabitants
who reached the age of 55 and people who migrated into the
research area since the start of RS-I. A total of 3011 (67.3%)
were enrolled, and baseline data were collected from 2000 to
2001. Besides the minimum age, there were no other criteria
for eligibility for participation in either of the cohorts.
For the present analysis, we excluded all participants with a
history of cardiovascular disease (coronary heart disease,
cerebrovascular disease, or heart failure) at baseline (n=1421),
those who did not visit the research centre at baseline for
assessment of cardiovascular risk factors (n=1034), those who
did not provide, or withdrew, informed consent for collection
of follow-up data (n=76), and those without any available
follow-up data (n=44). This left a total of 8419 people eligible
for the present analysis.
Data collection during follow-up
Follow-up started at the date of assessment of cardiovascular
risk factors at the research centre. Methods for the follow-up
and data collection in the Rotterdam Study have been described
in detail elsewhere.12 13 In brief, data on clinical outcomes are
collected continuously through an automated follow-up system
involving digital linkage of the study database tomedical records
maintained by general practitioners working in the research
area. Moreover, well trained research assistants affiliated with
the study regularly check the medical records of each participant
by hand for diagnoses of interest. Notes, outpatient clinic reports,
hospital discharge letters, electrocardiograms, and imaging
results are collected from general practitioner records and
hospital records. Subsequently, research physicians
independently adjudicate all data on potential events.
Afterwards, medical specialists whose judgments are considered
decisive review the potential cases. Information on vital status
is additionally obtained from the central registry of the
municipality of the city of Rotterdam.
Assessment of cardiovascular disease
outcomes
All participants were followed up for the occurrence of incident
coronary heart disease, cerebrovascular disease, heart failure,
other cardiovascular death, and non-cardiovascular death.
Definitions and procedures on the adjudication of cardiovascular
outcomes have been described in detail previously.6 12-14 In brief,
coronary heart disease was defined as fatal or non-fatal
myocardial infarction, surgical or percutaneous coronary
revascularisation procedure (as a proxy for unstable or
incapacitating angina), or death from coronary heart disease.12
Cerebrovascular disease was defined as stroke,13 transient
ischaemic attack,14 or carotid revascularisation procedure. In
accordance with the guidelines of the European Society of
Cardiology heart failure was defined as the combination of
typical symptoms and signs, confirmed by objective evidence
of cardiac dysfunction or a positive response to initiated
treatment.6 12Other deaths from cardiovascular disease included
all cardiovascular mortality other than fatal coronary heart
disease or fatal stroke, such as deaths from aortic aneurysms,
peripheral vascular disease, valvular heart disease, and
pulmonary embolisms.12
Hard coronary heart disease was defined as fatal and non-fatal
myocardial infarction or definite coronary mortality. Hard
cerebrovascular diseasewas defined as non-haemorrhagic stroke.
Other atherosclerotic cardiovascular deathsmainly encompassed
deaths from abdominal aortic aneurysms and peripheral vascular
disease. These definitions of hard atherosclerotic cardiovascular
disease correspond with the endpoints used in clinical trials and
guidelines for primary prevention of atherosclerotic
cardiovascular disease.
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Assessment of cardiovascular risk factors
Standardised assessment of anthropometrics, cardiovascular
risk factors, and use of drugs at baseline has been described in
detail for both RS-I15 and RS-II.16 In RS-I, diabetes mellitus was
defined as a random or post-load serum glucose concentration
≥11.1 mmol/L, or the use of drugs to lower blood glucose. In
RS-II, diabetes mellitus was defined as a fasting serum glucose
concentration ≥7.0 mmol/L, a non-fasting serum glucose
concentration ≥11.1 mmol/L (only if fasting serum was
unavailable), or the use of drugs to lower blood glucose. A
family history of premature myocardial infarction was defined
as having a parent, sibling, or child who experienced a
myocardial infarction at the age of ≤65. Use of drugs to lower
blood pressure was defined as the use of antiadrenergics,
diuretics, β blockers, calcium channel blockers, or
renin-angiotensin system modifying agents.
Statistical analysis
We used linear regression models or Mann-Whitney U tests for
continuous data and χ2 tests for categorical data to compare
baseline characteristics between men and women.
We calculated remaining lifetime risks for first incident
cardiovascular disease and its components (coronary heart
disease, cerebrovascular disease, heart failure, and other
cardiovascular death) for men and women at age 55, 65, 75, and
85.When older individuals are followed for longer time periods,
death from non-cardiovascular causes precludes the occurrence
of cardiovascular disease in many. Similarly, when first
manifestations of cardiovascular disease are studied, the
occurrence of one manifestation precludes consideration of any
subsequent cardiovascular disease event. The preclusion of
disease specific outcomes of interest by death or other outcomes
are referred to as competing risks.17 18 Standard application of
survival analysis, such as Cox regression and Kaplan-Meier
estimates, do not take competing risks into account as those
who develop competing events are censored. Consequently,
absolute risks are overestimated.17 18We therefore used amethod
that takes into account the occurrence of competing events to
compute lifetime cumulative incidences in left truncated data
with age as time scale.19 This enabled us to compute lifetime
risks with only 20.1 years of follow-up. Lifetime risk estimates
reflect the cumulative incidences to the age of last observation:
in our data the maximum age was 106.4 years for men and 107.0
years for women. In the setting of competing risks analysis, the
sum of the lifetime risks of cardiovascular disease and
competing non-cardiovascular death equals 1; the sum of the
lifetime risks of the different first manifestations of
cardiovascular disease equals the lifetime risk of cardiovascular
disease.17 18We computed the excess number of events occurring
over the lifespan in women compared with men (per 1000) by
subtracting the lifetime risk in men from the lifetime risk in
women for each of the manifestations of cardiovascular disease
and multiplying it by 1000.
To evaluate the effect of adjustment for cardiovascular risk
factors on sex differences, we quantified the association of sex
with the subdistribution hazard of cardiovascular disease (or
the specific first manifestations) and non-cardiovascular death
using the method proposed by Fine and Gray.20 Results are
presented for models that were unadjusted (model 1); adjusted
for age (as a linear covariate) and level of education (model 2);
and additionally adjusted for systolic and diastolic blood
pressure, concentrations of total and high density lipoprotein
cholesterol, diabetes mellitus, smoking status, family history of
premature myocardial infarction, body mass index (BMI), C
reactive protein concentration, use of drugs to lower blood
pressure, and use of statins (model 3).
Next, we used the data augmentation proposed by Lunn and
McNeil to enable direct comparisons between the effect
estimates of sex on specific first manifestations of cardiovascular
disease by traditional Cox regression.21 This allows inference
on the difference in cause specific hazard ratios of sex on
particular manifestations of cardiovascular disease in the
presence of competing manifestations and non-cardiovascular
death.18 We present P values from the fully adjusted models
(model 3).
To exclude the influence of differences in the inclusion of
“softer” events in coronary heart disease and cerebrovascular
disease, we then limited the analysis to first incident hard
atherosclerotic cardiovascular events.
As a secondary analysis, we also repeated the main analysis
with cardiovascular disease categorised as fatal or non-fatal. A
first manifestation of cardiovascular disease was considered
fatal if death occurred within 28 days of the event and death
was attributed to cardiovascular disease.
As participants of RS-II were enrolled six to eight years after
the baseline examination of the participants of RS-I, we allowed
for strata of cohorts in the regression analyses and repeated all
the analysis in each cohort separately. A total of 476 (5.7%)
individuals had missing values for one or more traditional
cardiovascular risk factors (range 0-2.5% per risk factor) and
other covariables were missing in up to 3.5% of the participants.
These missing values were handled separately for each cohort
by a single imputation with an expectation-maximisation
algorithm.22 We used the level of significance of P<0.05. All
measures of association are presented with 95% confidence
intervals. Data were handled and analysed with the IBM SPSS
Statistics version 21.0.0.1 (IBMCorp., Somers, NY), R version
3.0.0 and its libraries “cmprsk,” “etm,” and “mstate.”
Results
Baseline characteristics
On average women were older than men and had lower levels
of attained education (table 1⇓). Cholesterol concentrations and
BMI were generally higher in women, whereas men had higher
diastolic blood pressure and were more often smokers. Several
baseline characteristics differed between both cohorts, including
an overall increase in the level of highest attained education,
higher blood pressure, lower concentrations of total cholesterol,
more frequent use of statins, and higher BMI in RS-II. Also,
although still significant, sex differences in smoking status were
less pronounced in RS-II.
Lifetime risk of cardiovascular disease
During a total of 81 276 person years (median 13.5 years for
persons censored alive) of follow-up, 2888 participants
developed a cardiovascular disease event, which corresponds
to an incidence rate of 35.5 (95% confidence interval 34.2 to
36.9) per 1000 person years for any first manifestation of
cardiovascular disease. Of these 2888 events, 826 were coronary
heart disease, 1198 were of cerebrovascular origin, 762 were
heart failure, and 102 were other cardiovascular deaths. Of the
first cardiovascular disease events, 608 (21.1%) were fatal.
Another 1532 individuals died from non-cardiovascular causes,
and 20 participants were lost to follow-up over the course of
the study (mainly from emigration). In the analysis restricted
to hard atherosclerotic outcomes, we included 1700
cardiovascular events, of which 766 were hard coronary heart
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disease, 869 non-haemorrhagic stroke, and 65 other
atherosclerotic cardiovascular deaths. Table 2 and appendix
table A show details regarding the amount of follow-up and the
number of specific events observed in men and women of each
cohort.⇓
The overall lifetime risk of cardiovascular disease was similar
for men and women at the age of 55 (table 3⇓, fig 1⇓), with
67.1% (95% confidence interval 64.7% to 69.5%) for men and
66.4% (64.2% to 68.7%) for women. Remaining lifetime risks
of cardiovascular disease decreased with advancing age as the
incidence of competing non-cardiovascular death increased.
The decrease was larger for men than for women: for those aged
85 without cardiovascular disease the remaining lifetime risk
of cardiovascular disease was 52.0% (46.6% to 57.3%) in men
and 57.1% (53.9% to 60.3%) in women. The cumulative
incidence of cardiovascular disease in men increased steadily
with age, whereas in women up to the age of 70 the cumulative
incidence remained low and increased steeply thereafter (fig
1⇓).
First manifestation of cardiovascular disease
Although the overall lifetime risks of developing any
cardiovascular disease were similar for men and women, the
first manifestations were different (table 3⇓, fig 2⇓). At age 55,
lifetime risks of the first manifestations of cardiovascular disease
in men were 27.2% for coronary heart disease, 22.8% for
cerebrovascular disease, and 14.9% for heart failure versus
16.9%, 29.8%, and 17.5%, respectively, for women. For every
1000 women, this would translate into 102 fewer first
manifestations with coronary heart disease developing over the
lifespan, but 70 more with cerebrovascular disease and 26more
with heart failure when compared with men. With increasing
age, excess risk remained about the same for cerebrovascular
disease but decreased for coronary heart disease and heart
failure. Cerebrovascular disease and heart failure became the
most common initial manifestations for men free from
cardiovascular disease at age 75 or higher. In women,
cerebrovascular disease was the most common first
manifestation in the remaining lifespan at every age. Figure 2
shows the cumulative incidences for the various cardiovascular
disease manifestations⇓. In men, the cumulative incidence of
coronary heart disease is higher than that of cerebrovascular
disease and heart failure at all ages with the cumulative
incidences of the latter two catching up until age 70 and all
curves running about parallel thereafter. In women, the curves
were steeper for cerebrovascular disease and heart failure than
for coronary heart disease, especially at higher ages, indicating
that most cases of cerebrovascular disease and heart failure
occurred in the later part of the lifespan. Women were on
overage older thanmenwhen cardiovascular diseasemanifested,
which was the case for each of the separate cardiovascular
disease outcomes (appendix table B). In both men and women,
those with coronary heart disease as the first manifestation were
the youngest, followed by those in whom cardiovascular disease
manifested with cerebrovascular disease and heart failure; those
who died from other cardiovascular causes were the oldest.
In line with the pattern of later onset of cardiovascular disease
in women shown in figure 1⇓, hazards (that is, instantaneous
risks) were lower for women than men with respect to any first
cardiovascular event or death from non-cardiovascular causes
(table 4⇓). The adjusted cause specific hazard ratio of sex for
development of cardiovascular disease was not significantly
different from the hazard ratio for competing non-cardiovascular
death (Lunn and McNeil P=0.33 for model 3), which
corroborates with the comparable lifetime risk of cardiovascular
disease. There was a large sex difference in the unadjusted
hazards for the development of coronary heart disease as a first
manifestation of cardiovascular disease. Also, despite the overall
lower hazards of cardiovascular disease, women had a somewhat
higher hazard than men for developing cerebrovascular disease
but not for heart failure. The age adjusted hazard ratios (model
2) were generally similar to the ones additionally adjusted for
traditional and newer cardiovascular risk factors (model 3).
Even after adjustment for these risk factors, cause specific
hazard ratios for the sex differences remained significantly lower
for coronary heart disease than cerebrovascular disease (Lunn
and McNeil P<0.001 for model 3) or heart failure (Lunn and
McNeil P=0.010 for model 3). Competing risk regression, with
Fine and Gray models, yielded smaller hazard ratios than
traditional Cox models for all associations except for
cerebrovascular disease (table 4⇓). Estimates were similar in
both cohorts (appendix table C).
Hard atherosclerotic cardiovascular disease
Lifetime risks for hard atherosclerotic cardiovascular disease
were substantially lower than with the broad definition of
cardiovascular disease (table 5⇓, appendix fig A). For those
aged 55, the lifetime risk of atherosclerotic cardiovascular
disease was 43.2% (95% confidence interval 40.7% to 45.6%)
for men and 38.1% (36.2% to 40.1%) for women. For men and
women free from atherosclerotic cardiovascular disease at age
85, remaining lifetime risks were about 31%. Again sex
differences were apparent in the first manifestation of
atherosclerotic cardiovascular disease (table 5⇓, appendix fig
B). At age 55, lifetime risks of first manifestations of
atherosclerotic cardiovascular disease were 23.5% for hard
coronary heart disease and 17.8% for non-haemorrhagic stroke
in men versus 14.4% and 22.5%, respectively, in women. For
every 1000 women, this translates into 91 fewer first
manifestations of coronary heart disease over the lifetime and
48 more first manifestations of stroke compared with men. In
men coronary heart disease was the most common first
manifestation in the remaining lifespan except for those aged
≥85, whereas in women strokewas the predominant presentation
during the remaining lifespan at all ages, especially in older
people. Identical patterns of the first occurrence of
atherosclerotic cardiovascular disease outcomes by rising age
were observed as were seen for the broad cardiovascular disease
outcome, although the cumulative incidence of cerebrovascular
disease crossed that of coronary heart disease in women at a
somewhat higher age (appendix table D, appendix fig B).
Case fatality
In both men and women, fatality of the first manifestation of
cardiovascular disease increased with age, with women being
slightly more likely to have their cardiovascular disease
presenting with a fatal event (18.0% of first events in men aged
≥55 versus 20.9% in women, P=0.047), but this was
predominantly because of more fatal events in women at old
age (appendix fig C, appendix table E). Fatal first manifestations
of cardiovascular disease other than coronary heart disease,
cerebrovascular disease, or heart failure were rare in all age and
sex groups (tables 3 and 5⇓⇓).
Discussion
Within a contemporary prospective population based cohort of
the general population, we used competing risks analysis to
appropriately quantify lifetime risk of cardiovascular disease
and its first manifestations in both sexes. At age 55, the risk of
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developing any cardiovascular disease over the lifespan was
similar for men and women. We found large sex differences in
the initial manifestation of cardiovascular disease.Men are more
likely to develop coronary heart disease as a first event, while
women are more likely to develop cerebrovascular disease or
heart failure as a first event, although these manifestations
appear most often at older age.
According to data from various American cohort studies, about
60% of middle aged men and little over half of the middle aged
women develop cardiovascular disease during their remaining
lifespan.23We report higher estimates of lifetime cardiovascular
risk. These differences can be explained by our inclusion of
“softer” cardiovascular manifestations, such as transient
ischaemic attack and arterial revascularisation procedures. Such
manifestations generally have less impact on the lives of the
patients, but do significantly contribute to the overall burden of
consumption of healthcare and its associated costs.
An important point to consider is that within the Rotterdam
Study one of the soft coronary events, non-invasively managed
angina, was not adjudicated. Angina can constitute 34% of first
diagnoses of coronary heart disease in men and 42% in women,
though the contribution of new onset isolated angina to the
incidence of coronary heart disease is small after age 70.3Angina
is difficult to adjudicate, but based on these estimates of angina,
we covered about half of the angina events with the inclusion
of coronary revascularisations. These represent the more definite
and severe cases of unstable or incapacitating exertional angina.
The lack of non-invasively managed angina could have reduced
absolute risk difference for coronary heart disease between men
and women. We therefore also conducted an analysis restricted
to hard cardiovascular outcomes. In this analysis, overall lifetime
risk of cardiovascular disease was somewhat lower in women
than in men (38.1% v 43.2% at age 55) and excess risk
attenuated for both coronary heart disease and cerebrovascular
disease compared with the broad cardiovascular disease
endpoint. The pattern of sex differences, however, remained
the same: cardiovascular disease presented more often with
coronary heart disease in men and more often with
cerebrovascular disease in women.
The results of our regression analysis of the sex differences for
the various cardiovascular manifestations were not materially
affected by adjustment for cardiovascular risk factors (table 4⇓).
This indicates that variation in risk factors between men and
women does not explain the observed differences in risk. The
pattern of sex differences was less pronounced for first
manifestations of cerebrovascular disease based on the hazard
ratios compared with lifetime risks, while the sex difference in
hazards for heart failure even reversed in the adjusted models.
This might be explained by the fact that hazard ratios have a
more limited interpretation for the lifetime perspective24 and
even more so after adjustment for age as higher life expectancy
in women is one of the driving forces behind a high lifetime
risks.
Implications
The recently released British and American guidelines on
primary prevention of cardiovascular disease recognise the
importance of assessment of lifetime risk.25 26Most middle aged
women, even those with a moderate to high burden of risk
factors, are at (often falsely reassuring) low short term risk of
developing cardiovascular disease and thereby might still not
qualify for intensive preventive measures based on their global
10 year cardiovascular risk.27-29 Our results indicate that many
women have a lifetime risk of cardiovascular disease that is
similar to that of men. Clinicians should therefore be aware that
the risk of cardiovascular disease rises more steeply in women
at older age than in men and that a low 10 year risk might come
with a high lifetime risk. On the other hand, cardiovascular
disease manifests at higher ages in women than in men. Onset
of cardiovascular disease at older age might not have the same
impact as onset at younger age, which is not accounted for by
the use of lifetime risks.
The global cardiovascular risk scoring algorithms that are
currently recommended in the prevention guidelines no longer
include only coronary heart disease as the outcome of
interest.25 26 30-32 The British and American guidelines now
recommend consideration of the risk of stroke besides coronary
heart disease to identify people at high risk of cardiovascular
disease.25 26 32 Compared with the older guidelines based on
coronary risk, substantially more women will be considered at
high risk under these new guidelines and thereby qualify for
more intensive risk factor control.33 Our results on lifetime risk
of hard atherosclerotic cardiovascular disease (hard coronary
heart disease and stroke) support this as the estimates were only
somewhat lower in women than in men (table 5⇓). Despite that
most attention on current prevention guidelines has focused on
the indications for lipid lowering treatment, adequate control
of the main modifiable causes of stroke—hypertension and
smoking34—should remain top priorities for clinicians and policy
makers to reduce the population burden of cerebrovascular
disease.
We noticed that heart failure constitutes about a quarter to a
third of the first manifestation of cardiovascular disease in both
men and women. This is a substantial proportion, especially
given that by definition none of the cases of heart failure in our
study were preceded by overt coronary heart disease, which is
considered to be the most important cause of heart failure in
older people.35 The high risks and similarity in men and women
is in agreement with the results from three American population
based cohorts.36 In the light of primary prevention of
cardiovascular disease this finding once more emphasises the
need to also focus on risk factors other than hyperlipidaemia,
as lipid lowering treatment has so far not been proved beneficial
to reduce the risk of non-ischaemic heart failure. Lifestyle
modification and blood pressure control are the main targets for
prevention of heart failure, especially in women, in whom blood
pressure is known to play a more prominent role in the
development of heart failure than in men.37
Up to age 75, first manifestations of cardiovascular disease were
rarely fatal in our study, and case fatality of the first
manifestation of cardiovascular disease increased with age. The
European guidelines for prevention of cardiovascular disease
recommend the use of the SCORE algorithm, which can be used
to estimate the 10 year risk of fatal cardiovascular disease.30 31
A consequence of the use of fatal events only is that treatment
allocation, based on absolute risk thresholds from the SCORE
algorithm, disproportionately increases the likelihood for older
individuals to be considered as candidates for preventive
treatment. Unfortunately, the expected absolute benefit from
prevention wanes with advancing age because of the increased
risk of competing non-cardiovascular death.38 39
Limitations
Our study has some limitations that need to be considered.
Various different manifestations of cardiovascular disease were
adjudicated according to standardised definitions. We did not
have adjudicated events available on incident angina that was
managed with non-invasive treatment, non-fatal peripheral
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vascular disease, and non-fatal abdominal aortic aneurysms.
Within a subset of the RS-I cohort, surgery for abdominal aortic
aneurysms has been adjudicated, which represented only 1.3%
of the first manifestations of cardiovascular disease. Secondly,
as our results were obtained from a population aged ≥55 our
results cannot be directly generalised to younger individuals
who might have an even higher lifetime risk of cardiovascular
disease. Thirdly, the Rotterdam Study cohorts are predominantly
of European descent (97.8% white). This is relevant because
lifetime risk of cardiovascular disease and its manifestations
vary by race.40 Fourthly, as the incidence of cardiovascular
disease has decreased substantially over the past decades,
estimates of lifetime risk are subject to birth cohort effects. We
used data from a broad age range (age 55.0 to 106.2 at baseline)
with long follow-up (over 20 years) to ensure that individuals
from various birth cohorts contribute to different age specific
cumulative incidences and thereby reduce these effects.7 Also,
the long follow-up will mitigate the “healthy volunteer effect”
that is known to cause an underestimation of the actual incidence
of most diseases shortly after baseline in population based
studies that require active participation.41 Participation rates at
enrolment were similar for men and women in all age groups,11
therefore this is unlikely to explain the sex differences we
observed. Nonetheless, the lifetime risks of cardiovascular
disease in our study could be somewhat underestimated. Fifthly,
we did not take into account changes in treatment and risk
factors during follow-up in the multivariable regression models.
Finally, in younger women myocardial infarction more often
presents without the hallmark symptom of chest pain.42 This
compromises optimal recognition of coronary heart disease in
women and might thereby explain part of the observed sex
differences in first manifestation of cardiovascular disease in
our study.
Conclusions
Men and women of middle age have similar overall lifetime
risks of cardiovascular disease, with two out of three facing
some form of cardiovascular disease during their life. These
numbers underline that primary prevention of cardiovascular
disease is of paramount importance in both men and women.
There are, however, considerable differences in the first
manifestation of cardiovascular disease, with men being more
likely to develop coronary heart disease as a first event, while
women are more likely to have cerebrovascular disease or heart
failure as their first event, although these manifestations appear
most often at older age. Our results underscore the importance
of adequate control of risk factors for stroke and heart failure
in primary prevention of cardiovascular disease.
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Tables
Table 1| Baseline characteristics of study populations used to determine lifetime risk of cardiovascular disease and its first manifestations.
Figures are number of participants (percentage) unless stated otherwise
Rotterdam Study II (2000-01) (n=2374)Rotterdam Study I (1990-93) (n=6045)
Total (n=8419) P valueWomen (n=1368)Men (n=1006)P valueWomen (n=3758)Men (n=2287)
0.00364.6 (8.0)63.7 (7.1)<0.00169.7 (9.4)67.9 (8.3)67.6 (8.9)Mean (SD) age (years)
Education:
<0.001129 (9.7)62 (6.3)<0.0011024 (28.3)353 (15.7)1568 (19.1)Primary
789 (59.2)260 (26.2)1702 (47.0)755 (33.5)3506 (42.8)Lower/intermediate general
and lower vocational
283 (21.2)395 (39.8)738 (20.4)805 (35.8)2221 (27.1)Higher general and
intermediate vocational
131 (9.8)275 (27.7)159 (4.4)338 (15.0)903 (11.0)Higher vocational and
university
Mean (SD) blood pressure (mm Hg):
0.077142 (22)144 (21)0.24140 (22)139 (22)140 (22)Systolic
<0.00178 (10)81 (11)<0.00173 (11)75 (12)75 (12)Diastolic
0.013357 (26.5)221 (22.0)<0.0011149 (30.6)474 (20.7)2201 (26.2)Use of drugs to lower blood
pressure
<0.0016.0 (0.9)5.6 (1.0)<0.0016.8 (1.2)6.3 (1.2)6.4 (1.2)Mean (SD) total cholesterol
(mmol/L)
<0.0011.5 (0.4)1.2 (0.3)<0.0011.4 (0.4)1.2 (0.3)1.4 (0.4)Mean (SD) high density
lipoprotein cholesterol
(mmol/L)
0.14134 (9.9)82 (8.2)0.1357 (1.5)24 (1.1)297 (3.5)Use of statins
0.029124 (9.1)119 (11.8)0.42374 (10.0)214 (9.4)831 (9.9)Diabetes mellitus
Smoking status:
<0.001275 (20.5)267 (26.7)<0.001674 (18.5)696 (31.0)1912 (23.2)Current
519 (38.6)567 (56.8)1022 (28.1)1361 (60.5)3469 (42.1)Former
549 (40.9)165 (16.5)1945 (53.4)191 (8.5)2850 (34.6)Never
0.75219 (16.3)156 (15.8)0.006630 (17.5)326 (14.8)1331 (16.4)Family history of premature
myocardial infarction
<0.00127.5 (4.5)26.9 (3.4)<0.00126.7 (4.0)25.6 (3.0)26.5 (3.8)Mean (SD) BMI
0.1041.00 (0.40 to 2.50)0.90 (0.30 to 2.20)0.231.79 (0.89 to 3.30)1.78 (0.83 to 3.81)1.57 (0.70 to 3.21)Median (IQR) C reactive
protein (mg/L*)
BMI=body mass index, IQR=interquartile range.
*Because of skewed distribution.
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Table 2| First incident cardiovascular events during follow-up in study to determine lifetime risk of cardiovascular disease and its first
manifestation. Values are numbers of participants (percentage) unless stated otherwise
Rotterdam Study II (n=2374)Rotterdam Study I (n=6045)
Total (n=8419) Women (n=1368)Men (n=1006)Women (n=3758)Men (n=2287)
First incident event
180 (13.2)164 (16.3)1491 (39.7)1053 (46.0)2888 (34.3)Cardiovascular disease event
46 (3.4)81 (8.1)338 (9.0)361 (15.8)826 (9.8)Coronary heart disease
28 (2.0)44 (4.4)157 (4.2)188 (8.2)417 (5.0)Myocardial infarction
12 (0.9)25 (2.5)46 (1.2)81 (3.5)164 (1.9)Coronary revascularisation
6 (0.4)13 (1.3)17 (0.5)44 (1.9)80 (1.0)Coronary artery bypass grafting
6 (0.4)12 (1.2)29 (0.8)37 (1.6)84 (1.0)Percutaneous coronary intervention
6 (0.4)12 (1.2)135 (3.6)92 (4.0)245 (2.9)Other fatal coronary heart disease
98 (7.2)44 (4.4)674 (17.9)382 (16.7)1198 (14.2)Cerebrovascular disease
55 (4.0)23 (2.3)416 (11.1)231 (10.1)725 (8.6)Stroke
33 (2.4)17 (1.7)213 (5.7)133 (5.8)396 (4.7)Ischaemic stroke
10 (0.7)2 (0.2)35 (0.9)25 (1.1)72 (0.9)Haemorrhagic stroke
12 (0.9)4 (0.4)168 (4.5)73 (3.2)257 (3.1)Unspecified stroke
43 (3.1)20 (2.0)256 (6.8)151 (6.6)470 (5.6)Transient ischaemic attack
0 (0.0)1 (0.1)2 (0.1)0 (0.0)3 (0.0)Carotid revascularisation
28 (2.0)37 (3.7)430 (11.4)267 (11.7)762 (9.1)Heart failure
8 (0.6)2 (0.2)49 (1.3)43 (1.9)102 (1.2)Other cardiovascular death
75 (5.5)93 (9.2)791 (21.0)573 (25.1)1532 (18.2)Non-cardiovascular death
1113 (81.4)749 (74.5)1476 (39.3)661 (28.9)3999 (47.5)No event (censored alive)
Follow-up time
9564670942 23422 76981 276Total person time (person years)
7.4 (6.3 to 8.4)7.2 (5.9 to 8.3)13.2 (6.2 to 16.0)10.5 (4.8 to 15.3)8.6 (5.9 to 14.9)Median (IQR) (years)
7.7 (6.7 to 8.4)7.7 (6.8 to 8.4)16.2(15.2 to 17.1)16.0 (15.1 to 16.7)13.5 (7.7 to 16.2)Median (IQR) for participants censored alive (years)
IQR=interquartile range.
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Table 3| Remaining lifetime risks of first incident manifestation of cardiovascular disease by age
Excess events per 1000 women†P value
Lifetime risk (%)* (95% CI)
Age (years) and manifestation WomenMen
Age 55:
——51263293No of people
−70.3466.4 (64.2 to 68.7)67.1 (64.7 to 69.5)Cardiovascular disease
−102<0.00116.9 (13.5 to 20.4)27.2 (24.1 to 30.3)Coronary heart disease‡
70<0.00129.8 (27.7 to 31.9)22.8 (20.4 to 25.1)Cerebrovascular disease§
260.01417.5 (15.9 to 19.2)14.9 (13.3 to 16.6)Heart failure
−10.392.1 (1.6 to 2.7)2.3 (1.6 to 2.9)Other cardiovascular death¶
Age 65:
——48323001No of people
220.07765.6 (63.7 to 67.5)63.4 (61.1 to 65.7)Cardiovascular disease
−69<0.00114.7 (13.3 to 16.2)21.6 (19.6 to 23.6)Coronary heart disease‡
76<0.00130.3 (28.4 to 32.1)22.7 (20.7 to 24.7)Cerebrovascular disease§
140.11318.2 (16.7 to 19.7)16.8 (15.0 to 18.5)Heart failure
00.492.4 (1.8 to 3.0)2.4 (1.6 to 3.1)Other cardiovascular death¶
Age 75:
——31801648No of people
480.00663.4 (61.2 to 65.6)58.7 (55.8 to 61.6)Cardiovascular disease
−290.01412.5 (11.0 to 14.0)15.4 (13.2 to 17.5)Coronary heart disease‡
70<0.00128.9 (26.8 to 31.0)21.9 (19.4 to 24.3)Cerebrovascular disease§
110.2419.4 (17.6 to 21.2)18.3 (16.0 to 20.6)Heart failure
−40.262.7 (2.0 to 3.5)3.1 (2.1 to 4.2)Other cardiovascular death¶
Age 85:
——1296438No of people
510.05457.1 (53.9 to 60.3)52.0 (46.6 to 57.3)Cardiovascular disease
60.3811.6 (9.6 to 13.7)11.0 (7.6 to 14.3)Coronary heart disease‡
550.01724.8 (22.0 to 27.6)19.3 (15.1 to 23.5)Cerebrovascular disease§
60.4017.9 (15.5 to 20.4)17.3 (13.2 to 21.3)Heart failure
−160.0952.8 (1.7 to 3.9)4.4 (2.2 to 6.6)Other cardiovascular death¶
*Adjusted for competing non-cardiovascular death.
†Excess risk computed as absolute difference in remaining lifetime risk between men and women.
‡Coronary heart disease=myocardial infarction, coronary revascularisation, or death from coronary heart disease.
§Cerebrovascular disease=stroke, transient ischaemic attack, or carotid revascularisation.
¶Other cardiovascular death=all cardiovascular mortality other than fatal coronary heart disease or stroke.
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Table 4| Hazard ratios (95% confidence intervals) for risk of first incident cardiovascular disease event and non-cardiovascular death for
women compared with men (reference category). All regression analyses used follow-up time as time scale and were stratified on cohort
(see appendix table C for results per cohort)
Competing risks model*Traditional Cox model
Model 1 (unadjusted)
0.81 (0.76 to 0.88)0.75 (0.70 to 0.81)Cardiovascular disease
0.52 (0.46 to 0.60)0.48 (0.42 to 0.55)Coronary heart disease†
1.15 (1.02 to 1.29)0.99 (0.88 to 1.12)Cerebrovascular disease‡
0.95 (0.82 to 1.09)0.83 (0.72 to 0.96)Heart failure
0.79 (0.53 to 1.17)0.67 (0.45 to 1.00)Other cardiovascular death§
0.78 (0.71 to 0.86)0.68 (0.61 to 0.75)Non-cardiovascular death
Model 2¶
0.73 (0.67 to 0.79)0.62 (0.57 to 0.67)Cardiovascular disease
0.50 (0.43 to 0.58)0.42 (0.37 to 0.49)Coronary heart disease†
1.06 (0.94 to 1.20)0.83 (0.73 to 0.93)Cerebrovascular disease‡
0.79 (0.68 to 0.93)0.62 (0.53 to 0.72)Heart failure
0.72 (0.48 to 1.09)0.53 (0.35 to 0.80)Other cardiovascular death§
0.67 (0.60 to 0.74)0.51 (0.46 to 0.57)Non-cardiovascular death
Model 3**
0.76 (0.69 to 0.83)0.68 (0.62 to 0.75)Cardiovascular disease
0.51 (0.43 to 0.60)0.45 (0.37 to 0.53)Coronary heart disease†
1.16 (1.00 to 1.33)0.96 (0.83 to 1.11)Cerebrovascular disease‡
0.73 (0.61 to 0.88)0.62 (0.52 to 0.75)Heart failure
0.96 (0.61 to 1.50)0.73 (0.44 to 1.19)Other cardiovascular death§
0.76 (0.66 to 0.87)0.63 (0.55 to 0.71)Non-cardiovascular death
*Fine and Gray method for subdistribution regression with competing risks.20
†Coronary heart disease=myocardial infarction, coronary revascularisation, or death due to coronary heart disease.
‡Cerebrovascular disease=stroke, transient ischaemic attack, or carotid revascularisation.
§Other cardiovascular death=all cardiovascular mortality other than fatal coronary heart disease or stroke.
¶Adjusted for age (linear covariate) and level of education.
**Adjusted for age (linear covariate), level of education, systolic and diastolic blood pressure, concentrations of total and high-density lipoprotein cholesterol,
diabetes mellitus, smoking status, family history of premature myocardial infarction, body mass index, concentration of C-reactive protein, use of drugs to lower
blood pressure, and use of statins.
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Table 5| Remaining lifetime risks of first incident manifestation of hard atherosclerotic cardiovascular disease by age
Excess events per
1000 women†P value
Lifetime risk (%)* (95% CI)
Age (years) and manifestation WomenMen
Age 55:
——51263293No of people
−51<0.00138.1 (36.2 to 40.1)43.2 (40.7 to 45.6)Hard atherosclerotic cardiovascular event
−91<0.00114.4 (13.0 to 15.8)23.5 (21.4 to 25.6)Hard coronary heart disease‡
48<0.00122.5 (20.8 to 24.2)17.8 (15.8 to 19.7)Non-haemorrhagic stroke
−70.0371.2 (0.8 to 1.6)1.9 (1.3 to 2.6)Other atherosclerotic cardiovascular death§
Age 65:
——50033159No of people
−260.05037.8 (35.8 to 39.7)40.3 (38.0 to 42.7)Hard atherosclerotic cardiovascular event
−70<0.00113.7 (12.3 to 15.1)20.8 (18.8 to 22.7)Hard coronary heart disease‡
51<0.00122.8 (21.0 to 24.5)17.7 (15.8 to 19.5)Non-haemorrhagic stroke
−60.0571.3 (0.8 to 1.7)1.9 (1.3 to 2.6)Other atherosclerotic cardiovascular death§
Age 75:
——35601934No of people
70.3436.2 (34.1 to 38.4)35.5 (32.7 to 38.3)Hard atherosclerotic cardiovascular event
−48<0.00111.9 (10.5 to 13.4)16.8 (14.6 to 18.9)Hard coronary heart disease‡
62<0.00122.9 (21.0 to 24.8)16.7 (14.5 to 18.8)Non-haemorrhagic stroke
−60.0931.4 (0.9 to 1.9)2.1 (1.3 to 2.9)Other atherosclerotic cardiovascular death§
Age 85:
——1619594No of people
30.4631.6 (28.9 to 34.4)31.4 (26.9 to 35.8)Hard atherosclerotic cardiovascular event
−380.02310.3 (8.5 to 12.1)14.1 (10.8 to 17.4)Hard coronary heart disease‡
420.02620.2 (17.8 to 22.5)15.9 (12.4 to 19.4)Non-haemorrhagic stroke
−10.411.2 (0.5 to 1.8)1.3 (0.3 to 2.4)Other atherosclerotic cardiovascular death§
*Adjusted for competing non-atherosclerotic death among men and women at different ages.
†Excess risk computed as absolute difference in remaining lifetime risk between men and women.
‡Hard coronary heart disease=myocardial infarction or death from coronary heart disease.
§Other atherosclerotic cardiovascular death=all atherosclerotic cardiovascular mortality other than fatal coronary heart disease or non-haemorrhagic stroke.
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Figures
Fig 1 Cumulative incidence of cardiovascular disease (defined as coronary heart disease, cerebrovascular disease, heart
failure, and other cardiovascular death) and competing non-cardiovascular death for men and women aged 55. Coronary
heart disease was defined as myocardial infarction, coronary revascularisation, or death from coronary heart disease.
Cerebrovascular disease was defined as stroke, transient ischaemic attack, or carotid revascularisation. Other cardiovascular
death included all cardiovascular mortality other than fatal coronary heart disease or stroke
Fig 2 Cumulative incidence of first cardiovascular disease manifestations adjusted for competing non-cardiovascular death
for men (left) and women (right) aged 55. Coronary heart disease was defined as myocardial infarction, coronary
revascularisation, or death from coronary heart disease. Cerebrovascular disease was defined as stroke, transient ischaemic
attack, or carotid revascularisation. Other cardiovascular death included all cardiovascular mortality other than fatal coronary
heart disease or stroke
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